Ligand Pharmaceuticals Incorporated (LGND)

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Ligand Announces Closing of Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be...

Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be...

Form 8-K - Current report

Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ligand Announces 2026 Investor Day in New York City

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today...

Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today...

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end...

Form 8-K - Current report

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously...

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing...